Haemoglobin dynamics in Papuan and non-Papuan adults in northeast Papua, Indonesia, with acute, uncomplicated vivax or falciparum malaria

Walter RJ Taylor1,2*, Hendra Widjaja1, Hasan Basri1, Emiliana Tjitra3, Colin Ohrt4, Taufik Taufik5, Samuel Baso6, Stephen L Hoffman7 and Thomas L Richie1

Abstract

Background: Haemoglobin (Hb) recovers slowly in malaria and may be influenced by naturally acquired immunity. Hb recovery was compared in malaria immune, indigenous Papuan and non-Papuan adults with limited malaria exposure.

Methods: Hb concentrations were measured on Days (D) 0, 3, 7, and 28 in 57 Papuans and 105 non-Papuans treated with chloroquine, doxycycline or both drugs for acute, uncomplicated Plasmodium vivax (n = 64) or Plasmodium falciparum (n = 98).

Results: Mean (SD, range) D0 Hb was 12.7 (2.2, 7–21.3) g/dL and was similar in P. falciparum infected Papuans and non-Papuans: 12.2 vs 12.8 g/dL (P = 0.15) but significantly lower in: (i) P. vivax-infected Papuans vs P. vivax-infected non-Papuans: 11.4 vs 13.47 g/dL ([Δ] = −2.07 (95% CI: −3.3 – –0.8), P = 0.0018), (ii) all patients with splenomegaly (vs those without splenomegaly): 12.16 vs 13.01 g/dL ([Δ] = −0.85 (−1.6–−0.085), P = 0.029), and (iii) all females vs. all males: 10.18 vs 13.01 g/dL ([Δ] = −2.82 (−3.97 – –1.67), P < 0.0001). Multiple regression identified female sex (P = 0.000), longer illness duration (P = 0.015) (P. falciparum patients) and Papuan ethnicity (P = 0.017) (P. vivax patients) as significant factors for a lower D0 Hb. Mean D28 Hb increased to 13.6 g/dL ([Δ] = 1.01 (0.5–1.5) g/dL, vs D0 Hb, P = 0.0001). It was: (i) positively correlated with the D0 Hb (adjusted R² = 0.24, P = 0.000), and was significantly lower in P. vivax infected Papuans vs. non-Papuans: 12.71 vs 14.46 g/dL ([Δ] = −1.7 (−2.95–−0.5), P = 0.006).

Conclusions: Haemoglobin recovery was related to baseline Hb. Vivax-infected malaria immune Papuans had persistently lower Hb concentrations compared to non-Papuans with limited malaria exposure. This haematological disadvantage remains unexplained.

Keywords: Anaemia, Malaria, Papuans, Indonesia

* Correspondence: rob@tropmedres.ac
1The US Navy Medical Research Unit no. 2 (NAMRU-2), Jakarta, Indonesia
2Department of Tropical Medicine, Tulane University School of Public Health, New Orleans, USA
Full list of author information is available at the end of the article

© 2013 Taylor et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background

Malaria-associated anaemia is common and occurs in acute symptomatic infections, severe malaria, chronic asymptomatic infections, and inadequately treated or resistant infections [1-3]. Concomitant hookworm infestation, micronutrient deficiency, inherited blood disorders, and HIV compound the anaemic effects of malaria [4,5].

The main pathophysiological mechanisms in malaria related anaemia are the splenic removal of red cells, bone marrow suppression and dyserythropoiesis, and acute haemolytic anaemia (AHA) [1,6]. AHA may occur when parasitized red blood cells (PRBCs) are destroyed by the developing parasite and is potentially greater in *Plasmodium falciparum* because red blood cells of all ages are invaded and parasitaemia is high. *Plasmodium vivax* produces a low parasitaemia and invades only reticulocytes [7]. Malaria or drug-induced oxidant stress in patients with glucose-6-phosphate dehydrogenase deficiency may also produce AHA [8,9].

PRBCs and non-parasitized red blood cells (NPRBCs) are removed from the circulation but NPRBCs contribute much more to anaemia and this differs between the species. An estimated 34 NPRBCs in *P. vivax* [10] and eight NPRBCs in *P. falciparum* [2,11] are removed from the circulation for one PRBC. The splenic threshold for removing red cells is lowered in falciparum malaria [12] and splenic removal is directly related to spleen size [1,13]. Immune related changes to red cells results in their recognition and phagocytosis by activated monocytes and macrophages whilst others are trapped and destroyed in the splenic sinusoids [1,14]. In *P. falciparum*, NPRBCs and PRBCs have reduced deformability, making splenic trapping easier whilst, because of their increased size, vivax PRBCs have increased deformability but increased fragility, so splenic destruction is more likely [15-17]. The spleen also removes vivax (K. Chotivanich, unpublished data) and falciparum parasites from red cells and returns the deparasitized red cells back to the circulation, a process called pitting [13,18]; pitted RBCs cells also have reduced survival [19].

Depressed bone marrow function and dyserythropoiesis result in reduced red cell genesis and reticulocytocmia and poor bone marrow iron utilization is documented in *P. falciparum* despite adequate bone marrow stores [20]. Bone marrow changes may be related to cytokine imbalances in favour of raised TNF [21,22], the toxic effects of haemozoin [23], a blunted response to erythropoietin [24] and relative under-production of erythropoietin in adults [25].

With effective anti-malarial treatment, the mean haemoglobin (Hb) falls initially, reaching a nadir on Day 3 or Day 7 (most studies have collected data on these days only) and rises thereafter to stabilize at six weeks [2,26-28]. Reticulocytes increase and peak after 1 to 2 weeks [24,29], but the bone marrow may still be abnormal after three weeks [1,20].

Naturally acquired immunity to malaria (NAI) plays a role in limiting malaria-associated anaemia. In African children, the prevalence of anaemia, geometric mean parasite densities, and risk of fever with *P. falciparum* decrease with increasing age [30,31]. Consistent findings come from northeast Papua where, after approximately two years of intense malaria exposure, malaria naïve non-Papuan adults have similar malariometric indices (malaria prevalence rates, parasite densities, and malaria associated symptoms) as indigenous adult Papuans for *P. falciparum* but not for *P. vivax*. These data suggest the non-Papuan adults had acquired less protective immunity against *P. vivax* compared to *P. falciparum* [32,33].

There is a paucity of data on Hb dynamics and malaria-associated anaemia from NE Papua. Herein, a post hoc analysis of the Hb changes between malaria-immune, indigenous Papuans and non-Papuans from other parts of Indonesia with limited malaria exposure is reported.

Methods

The study took place from October 1995 to January 1998 at the Rumah Sakit Umum (RSU), a public hospital in Jayapura, the capital of Papua Province, Indonesia's most eastern province. Located on the northeast coast of Papua, Jayapura has low rates of malaria transmission but the surrounding lowland area is characterized by intense malaria transmission. Local malariometric data, study conduct and changes in the white blood cell and platelet counts in the same study patients have been detailed elsewhere [34-36]. Briefly, routine haematological parameters (Hb, total white cell and platelet counts) were measured and malaria films taken on Days (D) 0, 3, 7, and 28 during a trial of patients with acute symptomatic, uncomplicated vivax and falciparum malaria who were treated with either chloroquine (C) alone, chloroquine plus doxycycline (CD), or doxycycline (Dox) alone.

Parasite densities (N/μL) were calculated using the measured total white blood cell counts or assumed to be 8000/μL, if the white blood cell count was missing. Double entered and validated data (Epi Info 6.04b, Centers for Disease Control and Prevention, Atlanta, GA, USA) were analysed using Stata v8 (Stata Corporation, USA). Continuous data were compared by t test or one way ANOVA or the corresponding non-parametric tests, as appropriate. The relationship between two continuous variables was assessed by Pearson’s correlation coefficient (r) and coefficient of determination (R2) for normally distributed data or by Spearman Rho (skewed data). Proportions were compared by Chi-squared test or Fisher’s exact test. Backward stepwise multiple regression was performed to assess the independence of
Figure 1 The mean haemoglobin concentrations at Day 0 and during following up, illustrating the total malaria attributable fall in haemoglobin (MAFt) and the malaria attributable haemoglobin fall before treatment (MAFbt).

Figure 2 Haemoglobin dynamics for all falciparum and all the vivax-infected patients.
variables on the Hb concentrations; adjusted (a) R² values are reported.

Written, informed consent was obtained from all patients. The study was conducted according to the Indonesian Ministry of Health, the Indonesian Navy, the United States Navy and US Army regulations governing the protection of human subjects.

Definitions
Anaemia of any degree was defined as Hb concentrations of <13 and < 12 g/dL in males and females, respectively, and moderate anaemia as Hb < 11 g/dL for both sexes, adapted from the WHO [37].

The mean total malaria attributable fall in Hb following treatment (MAFt) was defined as the difference between the mean D28 Hb in those successfully treated (i.e. patients without parasites on D28, Hb28wp) and the mean nadir Hb concentration which, in this study, was Day 3 for both species combined (Figure 1) and for each species (Figure 2). The mean malaria attributable fall in Hb before treatment (MAFbt) was defined as the mean Hb28wp minus the mean D0 Hb (Figure 1). The relative MAFt (MAFtrel) was expressed as a percentage of the baseline Hb.

Results
General characteristics
A total of 162 adult patients (Papuans = 57, non-Papuans = 105) were recruited: *Plasmodium vivax* (n = 63), *P.* *falciparum* (n = 89), and mixed infections (n = 10). These were reclassified as *P. falciparum* (n = 9) and *P. vivax* (n = 1) based on which of the two species had the higher parasitaemia.

Males and females numbered 146 (15–44 years) and 16 (15-33y), respectively. Compared to the non-Papuans, the Papuans had a significantly longer: (i) median residential time, (ii) median time since the preceding episode of clinical malaria, (iii) duration of current illness, (iv) a higher spleen rate (by palpation), (v) a lower median vivax parasitaemia, and (vi) a higher rate of anaemia (Table 1).

Day 0 haemoglobin
Hb0 data were available for 152 patients. The mean (SD, range) D0 Hb concentration was 12.7 (2.2, 7–21.3) g/dL and was similar between the two species: *P. vivax* 12.9 (2.4) g/dL vs *P. falciparum* 12.6 (2.1) g/dL (P = 0.35).

Significantly lower mean D0 Hb concentrations (Table 2) were found in: (i) vivax-infected Papuans vs. non-Papuans, (ii) all patients with splenomegaly (n = 47): 12.16 vs. 13.01 g/dL (without splenomegaly, n = 105): Δ = −0.85 (−1.6–−0.085), P = 0.029, and (iii) all females (n = 14) 10.18 vs. 13.01 g/dL (males, n = 138): Δ = −2.82 (−3.97–−1.67), P < 0.0001.

There was a weak negative relationship between illness duration and D0 Hb (R² = 0.04) and no correlation between the D0 Hb and parasitaemias of both species (P = 0.77, P = 0.54). Multiple regression of the falciparum-infected patients identified female sex (P = 0.000) and illness duration (P = 0.015) as significant factors for a lower

| Table 1 Demographic, clinical and laboratory characteristics of the Papuan and non-Papuan study subjects at disease presentation |
|---------------------|---------------------|---------------------|
|                     | Papuans n = 57      | Non Papuans n = 105 |
| Age                 | 22 (15–39)          | 24 (15–44)          |
| Male: Female        | 48 : 9              | 98 : 7              |
| Residence in years  | 21.5 (15–39 y)      | 3 (2m to 24) y      |
| Previous clinical malaria*† | 2 (0–16)          | 3 (0–11)            |
| Time since last malaria attack‡ | 14w (8w-17m) | 9w (6w-5.6m) |
| Duration of illness in days† | 4 (1–30)          | 2 (1–30)            |
| Temperature‡        | 38 (36.5-41)        | 38.6 (36.1-41.3)    |
| Splenomegaly        | 26 (45.6%)          | 27 (25.7%)          |
| Anaemia§            | 34/52 (65.4%)       | 36/100 (36%)        |
| Moderate anaemia‡   | 16/52 (30.8%)       | 20/100 (20%)        |
| *P. falciparum* parasitaemia‡ | 3,007/20–64,998 | 2,346 (38–74,432) |
| *P. vivax* parasitaemia§ | 703 (55–9920)     | 2,592 (54–14124)    |

Continuous data are median (range) unless otherwise stated.
*1 number of previous malaria episodes by history.
*2 median (range).
*3 Anaemia = haemoglobin < 13 g/dL (male), & 12 g/dL (female).
*4 Moderate anaemia = haemoglobin < 11 g/dL both sexes.
*5 median (range).
In the vivax-infected patients, being Papuan (\(P = 0.017\)) was the only significant variable; it was also associated with a lower D0 Hb.

**Haemoglobin dynamics**

For all patients combined, the mean Hb concentration fell to nadir on Day 3: -0.19 (\(-9.4 - 4.2\)) g/dL \(\equiv -0.55 (-44.1 - 44.7)\%\); this fall was inversely related to baseline Hb (\(P = 0.000\), Additional file 1). By contrast, patients with baseline moderate anaemia had an initial rise on mean Hb (0.58 (\(-1.2 - 4.2\)) g/dL on D3) that was sustained to D28 (Figure 3).

For all patients combined, Hb dynamics were similar between the species (Figure 2), the falciparum infected Papuans (Figure 4), and the three drug arms (Additional file 2). The vivax-infected Papuans had a small mean rise in Hb by D3 (not significantly different to the small increase in the non-Papuans, \(P = 0.33\)) but had significantly lower mean Hb concentrations on D3-28 compared to the non-Papuans with *P. vivax* (Table 2 and Figure 5).

By D28, the mean Hb (n = 74 patients) had risen significantly (\(P = 0.0001\)) to 13.6 g/dL and there was a corresponding fall (\(P < 0.001\)) in the proportion of anaemic patients to 29.73% (22/74) vs baseline. The D28 Hb concentration was best explained by the D0 Hb concentration and sex (multiple regression): \(aR^2 = 0.32\) (\(P = 0.001\)); removing sex from the model resulted in an \(aR^2 = 0.24\) for D0 Hb.

**Malaria attributable fall in haemoglobin**

On Day 28, there were 65 patients who were parasite negative and had paired Hb3 and Hb28 data; their mean D28 Hb was 13.74 (SD 1.7, range 9.9-18.1) g/dL. The mean (range) MAFt and MAFtrel values were 1.41 (\(-1 - 5.6\)) g/dL and 12.3 (\(-8.5 - 62\)) %, respectively. The mean MAFbt was 1.07 (\(-7.9 - 6.2\)) g/dL, representing

### Table 2 Mean haemoglobin (standard deviation) and mean haemoglobin changes at follow up in Papuan and non-Papuan adults following treatment for *Plasmodium vivax* or *P. falciparum* malaria

| Day 0        | Papuans N | Non Papuans N | P    |
|--------------|-----------|---------------|------|
| Hb           | 11.85 (1.88) | 57            | 13.5 (2.27) | 105 | 0.009 |
| Males        | 12.27 (0.26) | 44            | 13.35 (0.22) | 94  | 0.005 |
| Hb falciparum | 12.16 (1.97) | 36            | 12.94 (2.18) | 53  | 0.1   |
| Hb vivax     | 11.4 (1.59) | 16            | 13.47 (2.35) | 47  | 0.001 |
| Day 3        |           |               |      |      |
| Hb           | 11.93 (2.02) | 46            | 12.86 (1.73) | 90  | 0.006 |
| Hb falciparum | 12.14 (2.12) | 31            | 12.65 (1.83) | 47  | 0.26  |
| Hb vivax     | 11.5 (1.78) | 15            | 13.09 (1.61) | 43  | 0.0024|
| \(\Delta Hb3\) Hb0 | -0.03 (\(-0.31 to + 0.24\)) | 46 | -0.27 (\(-0.63 to + 0.09\)) | 90  | 0.39  |
| \(\Delta Hb3\) Hb0 falciparum | -0.11 (\(-0.48 to + 0.25\)) | 31 | -0.17 (\(-0.6 to + 0.26\)) | 47  | 0.85  |
| \(\Delta Hb3\) Hb0 vivax    | 0.12 (\(-0.28 to + 0.53\)) | 15 | -0.38 (\(-0.99 to + 0.29\)) | 43  | 0.33  |
| Day 7        |           |               |      |      |
| Hb           | 12.2 (1.95) | 43            | 12.8 (1.76) | 83  | 0.1   |
| Hb falciparum | 12.28 (2.07) | 29            | 12.3 (1.71) | 40  | 0.96  |
| Hb vivax     | 12.06 (1.75) | 14            | 13.21 (1.71) | 43  | 0.035 |
| \(\Delta Hb7\) Hb0 | 0.31 (\(-0.05 to + 0.68\)) | 42 | -0.23 (\(-0.71 to + 0.12\)) | 83  | 0.059 |
| \(\Delta Hb7\) Hb0 falciparum | 0.17 (\(-0.28 to + 0.64\)) | 28 | -0.44 (\(-0.09 to +0.06\)) | 40  | 0.09  |
| \(\Delta Hb7\) Hb0 vivax | 0.56 (\(-0.07 to + 1.26\)) | 14 | -0.17 (\(-0.49 to +0.82\)) | 43  | 0.2   |
| Day 28       |           |               |      |      |
| Hb           | 13.07 (2.03) | 27            | 13.9 (1.49) | 47  | 0.038 |
| Hb falciparum | 13.23 (2.15) | 19            | 13.49 (1.54) | 25  | 0.64  |
| Hb vivax     | 12.71 (1.79) | 8             | 14.46 (1.28) | 22  | 0.006 |
| \(\Delta Hb28\) Hb0 | 1.15 (\(0.35 to 1.76\)) | 26 | 0.94 (\(0.25 to 1.63\)) | 47  | 0.66  |
| \(\Delta Hb28\) Hb0 falciparum | 1.06 (\(0.23 to 1.9\)) | 18 | 1.2 (\(0.3 to 2.1\)) | 25  | 0.82  |
| \(\Delta Hb28\) Hb0 vivax | 1.36 (\(0.46 to 2.26\)) | 8 | 0.64 (\(-0.48 to 1.75\)) | 22  | 0.44  |
75.8% (1.07/1.41) of the MAFt. MAFt and MAFtrel gave essentially the same results in all analyses so MAFtrel results are reported hereafter.

In bivariate analyses, MAFtrel was significantly: (i) negatively correlated with the D0 Hb (Pearson’s coefficient = −2.8, \(P = 0.0001\)), (ii) positively correlated with illness duration (\(P = 0.0005\)), (iii) higher (\(P = 0.0005\)) in patients with D0 moderate anaemia (\(n = 16\)) vs. those without moderate anaemia (\(n = 49\): 23.3\% vs. 6.6\% (these %s correspond to MAFt concentrations of 1.9 vs. 0.9 g/L), (iv) higher (\(P = 0.0067\)) in patients with splenomegaly (\(n = 24\)) vs. those without splenomegaly (\(n = 41\): 18.2\% vs. 8.8\% (MAFt concentrations of 2.03 vs. 1.05 g/L).

Non-significant MAFtrel factors included: (i) ethnicity: Papuan 10.9\% vs. non-Papuan 13.1\% (\(P = 0.53\)), (ii) drug treatment (\(P = 0.53\)): 7.3\% (C) vs. 12.6\% (CD) vs. 13.7\% (Dox), and sex (\(P = 0.36\)): 16.8\% (female) vs. 11.7\% (male).

Multivariate analysis in the falciparum infected patients (\(\alpha R^2 = 0.47\)), identified four significant variables: Papuan ethnicity and D0 Hb were inversely correlated whilst illness duration and splenomegaly were positively correlated (Table 3). There were no explanatory variables in vivax patients (\(\alpha R^2 = 0\)).

**Discussion**

This study has shown that, for all patients and when stratified by infecting species, haematological recovery was characterized by an initial fall in the mean Hb, followed by a rise, consistent with previous studies of falciparum and vivax malaria [2,38]. By contrast, patients
with moderate anaemia had an initial rise in mean Hb, suggesting they had longer illness durations, had reached their nadir Hb at presentation and were “primed” to respond to anti-malarial treatment.

For all patients, the initial fall in mean Hb was modest, ~0.2 g/dL (~0.5% vs D0 Hb), and was inversely related to the baseline Hb. The subsequent increase in mean Hb, measured by the MAFt, was 1.4 g/dL; this figure compares favourably to the ~1.2 g/dL and ~1.1 g/dL in falciparum-infected patients of all ages from western Thailand [2] and Laotian adults [28], respectively, whose follow up was longer (42 days).

The MAFtrel was used in these analyses as it might be better than the MAFt as marker of Hb recovery because it takes into account the baseline Hb. No independent factors were identified to explain the MAFtrel in the vivax patients, suggesting inadequate patient numbers. For the falciparum patients, a higher MAFtrel was associated with a lower D0 Hb, a longer illness duration and splenomegaly whereas a lower MAFtrel was associated with being Papuan; these four factors accounted for just under half of the variance of the MAFtrel. Interestingly, ethnicity was not significant in the bivariate analysis and when excluded from the multivariate analysis, the model was less good. Given that the falciparum infected Papuans had similar Hb dynamics as the non-Papuans; these statistical findings regarding the Papuans should be interpreted cautiously.

Longer illness duration and splenomegaly are factors associated with a lower D0 Hb which in turn is a stimulus for increased erythropoietin production. Thus, with treatment, the bone marrow response may be more robust as the suppressing effects of cytokines and haemoglobin on it are reduced and as spleen size reduces, so red cell survival increases [1,22-24]. Although the bone marrow response appears more robust in patients with a lower baseline Hb, they did not “catch up” with the non-anaemic patients by study end. Furthermore, the D28 and D0 Hbs correlated positively (the latter explained ~25% of the D28 Hb variance). Therefore, “if you start low, you finish low”, despite better MAFtrel values. Longer follow up would have given data on recovery times for the anaemic patients and may have shown, like Price et al. in Karen children and adults, that anaemic patient recover more slowly than those without anaemia [2]. Moderate anaemia (<11 g/dL) was common (~23%) at presentation and is in broad agreement with 18% found in the Karen, using a haematocrit <30% [2]. Factors associated with anaemia in the Karen were with age <5, splenomegaly, hepatomegaly, female sex, and prolonged illness, overlapping with some of the findings in the Papuan and non-Papuan adults.

The roles of ethnicity and NAI in the epidemiological context of NE Papuan are interesting questions. Data from this study suggest that the Papuans were haematologically disadvantaged when infected with P. vivax; they had persistently lower mean Hb concentrations post treatment compared to the non-Papuans. The indigenous Papuans had greater malaria exposure, because of their longer residence in Papua, suggesting that there may

Table 3 Multivariate analyses showing significant factors associated with the total malaria attributable fraction relative to the baseline haemoglobin in falciparum infected patients

| Independent variable     | Coefficient | 95% CIs       | P     |
|--------------------------|-------------|---------------|-------|
| Papuan ethnicity*        | −6.41       | −12.73 to −0.099 | 0.047 |
| Day 0 haemoglobin†       | −3.37       | −4.95 to −1.79 | 0.000 |
| Day 0 splenomegaly*      | 6.69        | 0.17 to 13.21  | 0.045 |
| Illness duration§        | 0.71        | 0.073 to 1.34  | 0.030 |
| Constant                 | 49.53       | 29.02 to 70.04 | 0.000 |

No factors were identified in the vivax infected patients.

* dichotomous variable (present yes / no).
† continuous variable measured in g/dL.
§ measured in days.
have been differences in NAI between the two groups. Data from this area show there is divergence in the acquisition of NAI for the two main malaria species. NAI to *P. falciparum* develops after approximately two years of intense transmission in newly arriving non-Papuans [32,33]. The median residence time for non-Papuans in this study was 3 years; thus, half or more of them probably had similar degrees of NAI to *P. falciparum* as the Papuans. Similar degrees of NAI against *P. falciparum* probably explain the similar baseline parasitaemia and mean Hb concentrations from baseline to D28 despite the initial fall in mean Hb for the non-Papuans. By contrast, NAI to *P. vivax* takes longer to acquire and NAI was higher in the Papuans as evidenced by their significantly lower median, baseline vivax parasitaemia; however, their vivax related NAI was not haematologically beneficial.

The Papuan haematological conundrum is unexplained and might represent host factors like G6PD deficiency, ovalocytosis, HIV, iron deficiency or pathophysiological factor/s unique to the Papuans that operate more in *P. vivax* infections, e.g. greater red cell fragility/splenic destruction, more cytokine induced bone marrow suppression, slower bone marrow recovery. These speculations underscore the lack of knowledge of the mechanisms of Hb dynamics in these two populations and call for further detailed investigation [39].

This study has several limitations. The analyses were supplementary to those of a small clinical trial of 162 adult patients and follow up was 28 days, two weeks before Hb stabilizes. By contrast, Price et al. analysed ~1,500 adults and children over 63 days [2]. The study herein reported was not designed *a priori* to detail the haematological responses; thus, key haematological parameters like the mean corpuscular volume, reticulocyte counts, iron metabolic parameters, G6PD status, presence of thalassaemia and ovalocytosis were not tested. Such data would be essential in a haematological investigation in ethnically diverse NE Papua.

To conclude, this study has shown similar Hb dynamics between vivax and falciparum malaria but unexplained differences between vivax-infected Papuans and non-Papuans.

**Additional files**

Additional file 1: The relationship between the absolute change in the initial fall (hbdiff30) in haemoglobin on Day 3 and the baseline haemoglobin concentration (hb0) in g/dL for the Papuans and non-Papuans combined.

Additional file 2: Box plots of haemoglobin dynamics as a function of treatment arms in all patients with both species. C = chloroquine alone, CD = chloroquine plus doxycycline, Dax = doxycycline alone.

**Competing interest**

None of the authors have a conflict of interest.

**Authors’ contributions**

CO conceived the original design. CO, WRJT, ET, SLH, TLR developed the protocol. WRJT, HW, HB, Taufik, ET, SB executed the study. WRJT analysed the data and wrote the first draft of the paper. TLR, SLH, CO, ET contributed significantly to revisions of the paper. All authors read and approved the final manuscript.

**Acknowledgments**

We are grateful to the patients for joining this study. The authors wish to thank the following for their contribution to the study: (i) the nurses at the Jayapura General Hospital and the Indonesian Naval Hospital (ii) Drs. Oyong (Jayapura General Hospital) and Kristanto (Indonesian Naval Hospital) for their support in study execution, (iii) Nona Nurjaya Kadir and Pak Feriyanto C. Sanggameloe for slide reading, laboratory work, and data management, (iv) Pak Pumomo Prodjodipuro, Sofyan Masbar, Awalludin Sutamiharja and Pak Suradi for slide reading (v) Dr. Budi Subianto, (Provincial Health Office, Jayapura) for facilitating study execution, (vi) Dr. Kasia Stepniowska for helping WRJT with some of the statistics. CO, SLH and TLR were active duty United States military personnel at the time they contributed to this work; HW and HB were Foreign Service nationals working for the US Government; and WRJT was an Intergovernmental Personnel Act employee working for the US Government. The work of these individuals was prepared as part of official government duties. Title 17 U.S.C. §101 defines a U.S. Government work as a work prepared by a military service member or employee of the U.S. Government as work of that person's official duties. Title 17 U.S.C. §106 provides that “Copyright protection under this title is not available for any work of the United States Government.” The work of authors affiliated with the US Naval Medical Research Unit #2 was supported by work unit number DoD 63002A M00101 HEX 2406. The study protocol for the clinical research presented in this manuscript was approved by the NAMRU-2 and Indonesian Ministry of Health Institutional Review Boards, in compliance with all applicable Federal regulations governing protection of human subjects. All study subjects gave written informed consent. The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Indonesian Military, the Indonesian Ministry of Health, the US Department of the Navy, the US Department of the Army, the US Department of Defense, or the US Government.

**Funding**

This study was funded by the US Naval Medical Research and Development Command (DoD 63002A M00101 HEX 2406).

**Disclaimer**

The views expressed in this paper are the authors’ and do not in any way represent those of the Indonesian Navy, the Indonesian Ministry of Health, or the US Navy.

**Author details**

1. The US Naval Medical Research Unit no. 2 (NAMRU-2), Jakarta, Indonesia.
2. Department of Tropical Medicine, Tulane University School of Public Health, New Orleans, USA.
3. Centre for Health Research and Development, National Institutes of Health, Jakarta, Indonesia.
4. Armed Forces Research Institute of Medical Science, Bangkok, Thailand.
5. Indonesian Naval Hospital, Jayapura, Papua, Indonesia.
6. Rumah Sakit Umum, Jayapura, Papua, Indonesia.
7. Naval Medical Research Center, Bethesda, MD, USA.

Received: 4 January 2013 Accepted: 5 June 2013
Published: 19 June 2013

**References**

1. Wickramasinghe SN, Abdalla SH: Blood and bone marrow changes in malaria. *Baillieres Best Pract Res Clin Haematol* 2000, 13:277–299.
2. Price RN, Simpson JA, Nosten F, Luxemburger C, Hikjapoen L, ter Kuile F, Chongsuvivatvong S, White NJ: Factors contributing to anemia after uncomplicated falciparum malaria. *Am J Trop Med Hyg* 2001, 65:614–622.
3. Brunel F, Gachot B, Wolff M, Regnier B, Danis M, Vachon F: Resurgence of blackwater fever in long-term European expatriates in Africa: report of 21 cases and review. *Clin Infect Dis* 2001, 32:1133–1140.
4. van Eijk AM, Ayisi JG, Ter en Kuile FO, Misere AO, Otieno JA, Kolczak MS, Koger PA, Steketee RW, Nahlen BL: Malaria and human immunodeficiency
22. Othoro C, Lal AA, Nahlen B, Koech D, Orago AS, Udhayakumar V, Phillips RE, Looareesuwan S, Warrell DA, Lee SH, Karbwang J, Warrell MJ, Anstey NM, Russell B, Yeo TW, Price RN: The rise and fall of the antimalarial Lapdap: a lesson in pharmacogenetics. Lancet 2010, 376:739–741.

23. Collins WE, Jeffery GM, Roberts JM: A retrospective examination of anemia during infection of humans with Plasmodium vivax. Am J Trop Med Hyg 2003, 68:410–412.

24. Bakker GD, de Donder E, Fikree FF: The importance of anaemia in native and transmigrant populations. Effects of age and history of exposure. Trop Geogr Med 1991, 43:481–486.

25. WHO: Iron deficiency anaemia: assessment, prevention and control: a guide for programme managers. Geneva: World Health Organization; 2001.